DBS System Company Profile

Background

DBS System SA, established in 2010, is a Swiss-based medtech company specializing in innovative blood collection technologies. The company has developed the HemaXis™ line of devices, which utilize patented microfluidic technology to enhance the collection, storage, and transportation of blood samples. This advancement aims to make blood sampling less invasive, more efficient, and cost-effective, thereby improving medical analysis and pharmaceutical research processes.

Key Strategic Focus

DBS System's strategic focus centers on revolutionizing blood sampling methods through its HemaXis™ devices. By integrating microfluidic technology, the company offers solutions that simplify the blood collection process while maintaining high-quality sample integrity. This approach targets the $20 billion blood sampling market, addressing the needs of pharmaceutical companies, university hospitals, and private laboratories in both the United States and Europe.

Financials and Funding

DBS System has secured approximately $3 million in funding, with its most recent Series A round completed over seven years ago. Notably, the company is part of the VERVE Ventures portfolio, indicating support from investors interested in health and biotechnology innovations.

Pipeline Development

The company's primary product line, HemaXis™, is designed to improve blood sample collection and processing. While specific development stages and timelines are not publicly disclosed, DBS System has engaged with large pharmaceutical companies and university hospitals as early adopters and testers. Additionally, the company is initiating projects with leading private laboratories in the U.S. and Europe, suggesting active efforts to expand its market presence.

Technological Platform and Innovation

DBS System's innovation lies in its proprietary microfluidic technology, which enables precise plasma/serum extraction and volume control in a standardized format. This technology enhances the reliability and efficiency of dried blood spot (DBS) samples in bioanalysis, offering a less invasive and more cost-effective alternative to traditional blood collection methods.

Leadership Team

The leadership team includes co-founders Eric Ödman and Julien Déglon. Eric Ödman has expressed appreciation for VERVE Ventures' support over the past five years, highlighting the value of their network and straightforward approach.

Competitor Profile

Market Insights and Dynamics

The global blood collection market is substantial, valued at approximately $20 billion. The demand for less invasive, cost-effective, and reliable blood sampling methods is driving innovation in this sector. DBS System's focus on microfluidic technology positions it to capitalize on these market trends.

Competitor Analysis

DBS System faces competition from companies offering alternative blood collection and analysis solutions. While specific competitors are not detailed in the available information, the company's unique microfluidic approach differentiates it within the market.

Strategic Collaborations and Partnerships

DBS System has established collaborations with large pharmaceutical companies and university hospitals, serving as early adopters and testers of its HemaXis™ devices. These partnerships are crucial for validating the technology and facilitating its adoption in clinical and research settings.

Operational Insights

By focusing on microfluidic technology for blood sampling, DBS System offers a distinct competitive advantage. Its HemaXis™ devices provide a less invasive, more efficient, and cost-effective solution compared to traditional methods, appealing to a broad range of clients in the medical and research fields.

Strategic Opportunities and Future Directions

DBS System is poised to expand its market presence by leveraging its innovative technology and existing partnerships. The company's ongoing projects with private laboratories in the U.S. and Europe indicate a strategic direction toward broader adoption and commercialization of its HemaXis™ devices.